Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics (KPTI) Stock Price & Analysis


KPTI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.11 - $6.01
Previous Close$1.25
Average Volume (3M)2.36M
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$237.33M
Total Debt (Recent Filing)$178.08M
Price to Earnings (P/E)-0.9
Nov 06, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding114,354,540
10 Day Avg. Volume1,063,111
30 Day Avg. Volume2,356,258
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)-1.83
Price to Sales (P/S)3.62
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside436.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $1.11 and its highest was $6.01 in the past 12 months.
    What is Karyopharm Therapeutics’s market cap?
    Currently, no data Available
    When is Karyopharm Therapeutics’s upcoming earnings report date?
    Karyopharm Therapeutics’s upcoming earnings report date is Nov 06, 2023 which is in 45 days.
      How were Karyopharm Therapeutics’s earnings last quarter?
      Karyopharm Therapeutics released its earnings results on Aug 02, 2023. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.342 by $0.052.
        Is Karyopharm Therapeutics overvalued?
        According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Karyopharm Therapeutics pay dividends?
          Karyopharm Therapeutics does not currently pay dividends.
          What is Karyopharm Therapeutics’s EPS estimate?
          Karyopharm Therapeutics’s EPS estimate is -$0.28.
            How many shares outstanding does Karyopharm Therapeutics have?
            Karyopharm Therapeutics has 114,354,540 shares outstanding.
              What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
              Karyopharm Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.342. Following the earnings report the stock price went down -0.556%.
                Which hedge fund is a major shareholder of Karyopharm Therapeutics?
                Among the largest hedge funds holding Karyopharm Therapeutics’s share is Platinum Investment Management. It holds Karyopharm Therapeutics’s shares valued at 895K.


                  Karyopharm Therapeutics Stock Smart Score

                  The Karyopharm Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Karyopharm Therapeutics

                  Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.


                  Top 5 ETFs holding KPTI

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold KPTI. The ETFs are listed according to market value of KPTI within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Corvus Pharmaceuticals
                  Kura Oncology
                  Corbus Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis